Novo Nordisk (NVO) GLP-1 Drug Regarded Safe for Brain by Oxford
ZacksOxford study demonstrates that Novo Nordisk’s (NVO) semaglutide is not associated with a risk of adverse neuropsychiatric outcomes compared with other antidiabetic medications over one year.